Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny)Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny)2070-9277Voronezh State Medical University named after N.N. Burdenko - The State Budgetary Institution of Higher Professional Education «Voronezh State Medical University named after N.N. Burdenko» of the Ministry of Public Health of the Russian675010.18499/2070-9277-2019-22-3-95-99Original ArticlePOSSIBILITY OF USING OF PETAL DIAGRAMS FOR QUANTITATIVE ESTIMATION OF PYRIDOSTYGMINE BROMIDE IN THEDOSAGE FORMAlekhinaM. I-NikitinaT. N-Voronezh State Medical University15122019223959903042021Copyright © 2019, Прикладные информационные аспекты медицины2019The article consist information about the possibility of using petal diagrams that was constructed from the results of spectrophotometric studies to doqualitative and quantitative determinationof pyridostigmine bromide in the Kalimine 60 N. Pyridostigmine bromide - the main ingredient of the anticholinesterase drug Kalimin 60 N - is used in the treatment of myasthenia gravis, myasthenic syndrome and other diseases associated with impaired neuromuscular conduction. The method of UV-spectrophotometry is one of the express and informative methods of pharmacopeia’s analysis, which currently use in analytical laboratories. It was shown that the petal diagrams make a more vivid two-dimensional representation of the spectra of solutions of the substance and the dosage form, and allow us to estimate the rate of change of the amount of the active substance during storage of the dosage form. It was shown that the obtained profiles of the substance and the drug completely match only if the drug consist right amount of original and good quality active substance.pharmaceutical analysisidentificationquantificationpetal diagrampyridostigmine bromideKalimin 60 Nфармацевтический анализидентификацияколичественное определениелепестковая диаграммапиридостигмина бромидКалимин60 Н[Государственная Фармакопея Российской Федерации. Издание XIV. Т. 1. ОФС.1.2.1.1.0003.15 Спектрофотомерия в ультрафиолетовой и видимой областях.- Москва, 2018. - С. 749 - 758. - Режим доступа: http://resource.rucml.ru/feml/pharmacopia/14_1/HTML/751/index.html (Дата обращения: 18.03.2019).][Государственная Фармакопея Российской Федерации. Издание XIV. Т. 1. ОФС.1.2.1.2.0005.15 Высокоэффективная жидкостная хроматография. - Москва, 2018.- С. 894 - 910.- Режим доступа: http://resource.rucml.ru/feml/pharmacopia/14_1/HTML/897/index.html (Дата обращения: 18.03.2019).][НД П N015236/01-240510 от 06.10.2008. Министерство здравоохранения и социального развития Российской Федерации. [ND П N015236/01-240510 from 06.10.2008. Ministry of Health and Social Development of the Russian Federation. (InRussian)].][Фармакопея США: USP 29; Национальный формуляр: NF 24: в 2 т.: [пер. с англ.]. - Москва : ГЭОТАР-Медиа, 2009. - T.1. - С. 1386-1387][European Pharmacopeia 9.0. - 2016. -Vol. 1. - P. 3450.][Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis / Jorge Enrique Machado-Alba [et al.] // Muscle & Nerve. -2017. -Vol. 56(6).- P. 1041-1046: doi: 10.1002/mus.25625][Thanvi B. R. Lo T C N Update on myasthenia gravis / B.R. Thanvi / / Postgrad Med J.- 2004.- Vol. 80.- P. 690 - 700: doi: 10.1136/pgmj.2004.018903][USP SertificatePyridostigmine bromide Cat. N 1586009. - USP Rockville, MD LOT J0G251.]